EGCG inhibition of the overexpressed dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) protein has shown benefits in neuronal plasticity processes in DS patients [85], which may be another potential molecular pathway to study in FASD and a therapeutic target for cognitive disorders. The gene discussed is DYRK1A; the disease is Cognitive impairment.